Now Playing
Opinion|Videos|June 28, 2024
Biologics Utilization Impacting US Health Care Spending
Eric Tichy, PharmD, MBA, BCPS, FCCP, FAST, and Chad Cannon, PharmD, BCCCP, open a panel discussion highlighting specialty biologics and navigating challenges for biosimilar uptake.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- How significant is the impact of specialty medications, particularly biologics, on current US health care spending?
- What have been the major challenges and successes in reducing health care costs through the use of biosimilars?
- Briefly, what is hindering biosimilar uptake?
- Where have biosimilars been successful?
- What are some strategies for successful biosimilar adoption?
Advertisement
Related to this article
Stigma, years-long diagnostic delays, and limited follow-up after a crisis remain hurdles for people with serious mental illness, experts say.
MedHaul’s platform streamlines nonemergency medical transportation, boosting on-time oncology visits, reducing costs, and helping patients reach critical care across underserved regions.
A 39,669-patient French cohort found ustekinumab and IL-23 inhibitors carry the lowest infection risk among biologics.
CMS' rule ending Medicaid and CHIP funding for pediatric sex-rejecting procedures is now in effect.
At a roundtable in Cleveland, kidney experts said IgA nephropathy and FSGS often go unrecognized, calling for EHR flags and better referral channels.
Labial gland biopsy may support diagnosis of neurologic Sjögren disease, especially when antibody tests are negative or inconclusive.
This analysis in RR MCL shows CAR T-cell therapy (brexucabtagene) yields higher complete responses vs bispecific antibodies; durability remains unclear.
Meta-analysis finds oral JAK inhibitors like baricitinib and ritlecitinib drive strong alopecia areata hair regrowth, improving SALT scores with manageable safety.
Advertisement
Advertisement
Trending on AJMC
1
Oral JAK Inhibitors Boost Hair Regrowth Odds in Alopecia Areata
2
CMS Rule Ends Medicaid, CHIP Funding for Pediatric Gender Care
3
Medicare Drug Price Negotiations Yield Uneven Out-of-Pocket Savings
4
Follitropin Delta Achieves Ongoing Pregnancy in 64% Under Age 35
5